- Home
- VSTM vs AMLX Comparison
VSTM vs AMLX Comparison
Compare VSTM & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- AMLX
- Stock Information
- Founded
- VSTM 2010
- AMLX 2014
- Country
- VSTM United States
- AMLX United States
- Employees
- VSTM N/A
- AMLX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- AMLX Health Care
- Exchange
- VSTM Nasdaq
- AMLX Nasdaq
- Market Cap
- VSTM 662.8M
- AMLX 749.9M
- IPO Year
- VSTM 2012
- AMLX 2022
- Fundamental
- Price
- VSTM $9.92
- AMLX $10.51
- Analyst Decision
- VSTM Strong Buy
- AMLX Strong Buy
- Analyst Count
- VSTM 9
- AMLX 7
- Target Price
- VSTM $13.38
- AMLX $12.29
- AVG Volume (30 Days)
- VSTM 2.9M
- AMLX 1.4M
- Earning Date
- VSTM 11-05-2025
- AMLX 11-06-2025
- Dividend Yield
- VSTM N/A
- AMLX N/A
- EPS Growth
- VSTM N/A
- AMLX N/A
- EPS
- VSTM N/A
- AMLX N/A
- Revenue
- VSTM $2,137,000.00
- AMLX N/A
- Revenue This Year
- VSTM $86.06
- AMLX N/A
- Revenue Next Year
- VSTM $395.22
- AMLX N/A
- P/E Ratio
- VSTM N/A
- AMLX N/A
- Revenue Growth
- VSTM N/A
- AMLX N/A
- 52 Week Low
- VSTM $2.40
- AMLX $2.28
- 52 Week High
- VSTM $11.25
- AMLX $10.64
- Technical
- Relative Strength Index (RSI)
- VSTM 66.95
- AMLX 72.14
- Support Level
- VSTM $8.71
- AMLX $9.15
- Resistance Level
- VSTM $11.25
- AMLX $10.06
- Average True Range (ATR)
- VSTM 0.64
- AMLX 0.55
- MACD
- VSTM 0.05
- AMLX 0.13
- Stochastic Oscillator
- VSTM 64.05
- AMLX 95.22
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.